

[Chem. Pharm. Bull.]
25(9)2249-2256(1977)

UDC 547.92.04 : 615.324.011.5

Studies on the Synthesis of Cardiotonic Steroids. III.¹⁾ New and Effective Route to Bufadienolides

EIICHI YOSHII, TAKIKO ORIBE, TORU KOIZUMI, ICHIRO HAYASHI,
and KUMIKO TUMURA

Faculty of Pharmaceutical Sciences, University of Toyama²⁾

(Received January 10, 1977)

An efficient synthetic method of bufa-20,22-dienolides from 20-ketopregnanes has been developed. The method involves the following reaction sequence: (1) 21-methoxymethylenation, (2) 2-methoxydihydropyran formation by reaction with excess dimethylsulfonium methylid, (3) transformation to buf-20(22)-enolide structure, (4) dehydrogenation to bufa-20,22-dienolide. Application of this attractive device to readily available 3 β -acetoxy-5 β -pregn-14-en-20-one established a new route to resibufogenin and bufalin.

Keywords—bufa-20,22-dienolide; buf-20(22)-enolide; resibufogenin; bufalin; anhydrobufalin; α -pyrone

The bufadienolides which occur in the toad venoms as well as in certain plant extracts³⁾ are well-known for their significant physiological features such as heart stimulating⁴⁾ and antitumor activities.⁵⁾ The representative members of these substances are bufalin (1) and resibufogenin (2) isolated from Ch'an Su (galenical preparation from Chinese toad secrete). Approach to the synthesis of natural bufadienolides has a history of over 30 years. The main difficulty encountered was, as discussed in a review,⁶⁾ to build both α -pyrone ring and labile 14 β -hydroxy (or epoxide) together at the D-ring keeping thermodynamically unstable configurations. In 1969, Sondheimer announced first formal total synthesis of 1 and 2, ingeniously solving this problem.⁷⁾ Shortly afterward, Hoechst Farbwerke workers⁸⁾ had developed attractive and methodologically different routes as exemplifies by the synthesis of scillarenin. Meanwhile, G.R. Pettit and his coworkers⁹⁾ also have made valuable contributions to the bufadienolide chemistry including the conversion of digitoxigenin (cardenolide) to some bufadienolides.¹⁰⁾

Those pioneering syntheses, however, involved multistep reaction sequence even from the relay steroids which themselves are not conventionally available. To circumvent this draw-

- 1) Part II: E. Yoshii, T. Koizumi, S. Mizuno, and E. Kitatsuji, *Chem. Pharm. Bull.* (Tokyo), **24**, 3216 (1976).
- 2) Location: Gofuku, Toyama, 930, Japan.
- 3) L.F. Fieser and M. Fieser, "Steroids," Reinhold Publishing Corp., New York, 1959, Chapter 20; P.G. Marshall, "Rodd's Chemistry of Carbon Compounds," 2nd ed., Vol. II, Part D, ed. by S. Coffey, Elsevier Publishing Co., 1970, Chapter 17.
- 4) K.K. Chen and A. Kovarikova, *J. Pharm. Sci.*, **56**, 1535 (1967); H. Murase, *Jpn. J. Pharmacol.*, **15**, 72 (1965); W. Foester, *Acta Biol. Med. Ger.*, **9**, 341 (1962) [*Chem. Abstr.*, **58**, 11846 (1963)]; Ch. Tamm, "Proceedings of the First International Pharmacological Meeting," Vol. III, ed. by W. Wilbrandt and P. Lindgren, Pergamon Press, London, 1963, pp. 11-26.
- 5) S.M. Kupchan, J.L. Moniot, C.W. Sigel, and R.J. Hemingway, *J. Org. Chem.*, **36**, 2611 (1971); S.M. Kupchan, R.J. Hemingway, and J.C. Hemingway, *ibid.*, **34**, 3894 (1969); J.L. Hartwell and B.J. Abbott, *Advan. Pharmacol. Chemother.*, **7**, 117 (1969).
- 6) F. Sondheimer, *Chemistry in Britain*, **1965**, 454.
- 7) F. Sondheimer, W. McCrae, and W.G. Salmond, *J. Am. Chem. Soc.*, **91**, 1228 (1969).
- 8) U. Stache, K. Radsch, W. Fritsch, W. Haede, H. Kohl, and H. Ruschig, *Ann. Chem.*, **750**, 149 (1971); W. Haede, W. Fritsch, K. Radsch, U. Stache, and H. Raschig, *ibid.*, **741**, 92 (1970).
- 9) Y. Kamano, G.R. Pettit, M. Tozawa, Y. Komeichi, and M. Inoue, *J. Org. Chem.*, **40**, 2136 (1975) and preceding papers.
- 10) G.R. Pettit and Y. Kamano, *J. Am. Chem. Soc.*, **94**, 8592 (1972).




Chart 1

back we previously communicated¹¹⁾ a facile preparative method of a key intermediate in Hoechst synthesis, 21,21-dimethoxy-5 β -pregnan-14-en-3 β -ol-20-one (3), from which 1 and 2 could be obtainable *via* 14-anhydrobufalin (21). Our continuing effort in this field of investigation has now yielded more effective short-step synthesis of these two natural bufadienolides which constitutes the present paper.

The starting steroid we decided to utilize was again 5 β -pregn-14-en-3 β -ol-20-one acetate (7b).¹²⁾ Here, α -pyrone synthesis from the side chain was sought in the report of Harris, *et al.*¹³⁾ As depicted below, two methylene transfer to 21-methoxymethylidene derivative (4) by the reaction with excess dimethylsulfonium methylide should produce methoxydihydropyran (5) which on subsequent appropriate operations might be convertible to 14-olefinic bufadienolide (6).




Chart 2

First, model experiment utilizing the 14,15-saturated compound, 3 β -acetoxy-5 β -pregnan-20-one (7a), is described. The aldehyde 8a was obtained by perchloric acid catalyzed condensation of 7a with trimethyl orthoformate.¹⁴⁾ It was then shortly warmed with weakly acidic methanol to produce a mixture of β -methoxyvinyl ketone (9a) and the dimethylacetal (10a) which, upon brief treatment with potassium *tert*-butoxide, was transformed to single product 9a in 76% yield. The reaction of 9a with large excess of dimethylsulfonium methylide followed by treatment of the crude product with methanolic hydrogen chloride afforded methoxydihydropyran (11a) and furan (12a), in the yield of 61% and 15% respectively. Hydrolysis of the methyl ether function of acetylated 11a was effected with boron trichloride in dichloromethane in the cold or preferably by warming with buffered hydrochloric acid (90–100% yield). Jones oxidation of the resulting pyranol (13a) produced buf-20(22)-enolide (14a). The final step leading to α -pyrone ring (17a) was then attempted after the method of

11) E. Yoshii, T. Miwa, T. Koizumi, and E. Kitatsuji, *Chem. Pharm. Bull.* (Tokyo), **23**, 462 (1975).

12) E. Yoshii, T. Koizumi, H. Ikeshima, K. Ozaki, and I. Hayashi, *Chem. Pharm. Bull.* (Tokyo), **23**, 2496 (1975).

13) C.M. Harris, J.J. Cleary, and T.M. Harris, *J. Org. Chem.*, **39**, 72 (1974).

14) J.P. Dusza, J.P. Joseph, and S. Bernstein, *J. Am. Chem. Soc.*, **86**, 3908 (1964).




Chart 3

Sarel, *et al.*¹⁵⁾ who had been successful in converting 5 β -buf-20(22)-enolide (**14c**) derived from cholanolic acid into the corresponding bufa-20,22-dienolide (**17c**) by dehydrogenation with 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) under proper choice of acid catalyst, toluene-*p*-sulfonic acid. The reaction of **14a** with DDQ under the same set of reaction conditions, however, resulted in predominant formation of the extended conjugate system, **15a** and **16a**. Only trace amount of the desired α -pyrone (**17a**) was noticed, irrespective of the nature of acid catalyst (both toluene-*p*-sulfonic acid and hydrogen chloride).

Since it was hardly understandable that the presence of 3-acetoxy function in **14a** affects the course of the dehydrogenation, we decided to examine whether the data of the literature is reliable or not. The Sarel's compound (**14c**) was therefore prepared, at our hand from 5 β -pregnan-20-one by the same route employed for the preparation of **14a** and subjected to DDQ dehydrogenation under exactly the same reaction condition as indicated in the literature. Again, almost exclusive formation of bufa-17,22-dienolides, **15c** and **16c**, was observed. Although the reason for the discrepancy of the above result from Sarel's is not clear at present, preferential removal of 17-H could be rationalized by consideration of the mechanism of quinone dehydrogenation which has been believed to involve hydride transfer.¹⁶⁾ The positive charge at C₂₁ developing along the reaction coordinate must be less stable than the one yielding at C₁₇ because of electron withdrawing nature of the ester substituent, and thus 21-H abstraction should be energetically less favorable as observed in the present experiment.¹⁷⁾

15) S. Sarel, Y. Shalon, and Y. Yanuka, *Chem. Comm.*, **1970**, 80, 81.

16) H.O. House, "Modern Synthetic Reactions," Benjamin Inc., California, 1972, pp. 37-44.

17) Private communication from Prof. Sarel, establishing the identity of our **14c** with theirs (NMR comparison), informed us that it takes some experience to effect α -pyrone formation.




Chart 4

Although we were bewildered by the unreplicable literature precedent and furthermore other dehydrogenating methods such as utilizing sulfur or palladium charcoal did not give fruitful result, the objective conversion could have eventually been accomplished by simple operation, bromination-dehydrobromination.¹⁸⁾ Thus, by addition of bromine to **14a,c** followed by mild treatment of the crude product with 1,5-diazabicyclo[5,4,0]undec-5-ene (DBU), there were obtained the bufadienolides **17a,c** in good yields.¹⁹⁾

Having been accomplished a simple access to bufadienolide structure, experiment was now advanced to the synthesis of natural 14 β -oxygenated bufadienolides (**1** and **2**). For this purpose, 3 β -acetoxy-5 β -bufa-14,20(20)-dienolide (**14b**) was prepared from **7b** utilizing the same reaction sequence as performed in the model experiment (Chart 3). Here, the remaining task might in principle be accomplished by either first transformation to bufa-20,22-

dienolide structure and subsequent introduction of 14 β -oxygen functions, or vice versa. Of the two routes the former one was first investigated.

Bromination-dehydrobromination method employed in the preliminary experiment could not be applicable for **14b**, since bromine addition occurred preferably at the more reactive 14-double bond. It occurred to us that selective bromine substitution at the position 23 (or 20) of **14b** could be achieved, if the position is activated by the formation of enoly silyl ether.²⁰⁾ The subsequent dehydrobromination was expected to proceed without difficulty to give α -pyrone ring. The model experiment utilizing **14a**, however, revealed




Chart 5

this idea to be unpromising. Trimethylsilylation of **14a** with trimethylchlorosilane—trimethylsilylimidazole²¹⁾ proceeded smoothly at room temperature to give a silylated product (**18**, R=Si(CH₃)₃), which on bromination in the cold afforded bromine containing butenolide (**20**). The reasonable explanation of this outcome should be that the silylation product under-

18) R.J. Chorvat and R. Papp, *J. Org. Chem.*, **41**, 2864 (1976).

19) **17a** has been previously prepared from dehydroepiandrosterone by performing over 10 steps, G.R. Pettit and J.R. Dias, *J. Org. Chem.* **36**, 3207 (1971).

20) R.H. Reuss and A. Hassner, *J. Org. Chem.*, **39**, 1785 (1974); L. Blanco, P. Amice, and J.M. Conia, *Synthesis*, **1976**, 194.

21) B. Baume, W.E. Wilson, and E.C. Horning, *Anal. Lett.*, **1968**, 401.

went rearrangement to **19** ($R=Si(CH_3)_3$) which was actually brominated. Similarly, the enolate formation (**18**, $R=Li$) at -78° followed by bromination²²⁾ resulted in the production of **20** again, showing facile fragmentation of 3,6-dihydro-2H-pyran-2-one to conjugated dienoate (**19**) *via* enolate²³⁾ or enol silyl ether. So far, the only successful method for the conversion of **14b** to 14-anhydrobufalin (**21**) has been sulfur dehydrogenation. However, the yield was unfortunately not acceptable owing to the concomitant formation of polar unidentified byproducts.




Chart 6

The second approach which involves the oxygenation of the 14-double bond of **14b** followed by α -pyrone formation has revealed to be quite effective. The reaction of **14b** with slight excess of aqueous N-bromoacetamide afforded unstable 15 β -bromo-14 β -hydrin which on alumina chromatography was readily transformed to 14 β ,15 β -epoxide (**22**). Addition of bromine to **22** in the presence of an acetate buffer and subsequent dehydrobromination with DBU did provide resibufogenin acetate (**23**) which was identical with the sample prepared from natural resibufogenin. Since hydrolytic removal of the acetate group giving resibufogenin and its conversion to bufalin by reductive cleavage of the epoxide ring are already recorded,²⁴⁾ the objective of the present investigation has thus been accomplished.

Experimental

All melting points are uncorrected. The infrared (IR) spectra were determined with JASCO IRA-1 or IR-S. The proton nuclear magnetic resonance (NMR) spectra were determined at 60 MHz with a Varian EM-360 or JEOL PMX-60. The chemical shifts are expressed in δ values relative to Me_4Si internal standard. The mass spectra were obtained with JEOL JMS-01SG-2 at 75 eV ionization potential. All reactions involving strong bases or organometallic reagents were performed under argon atmosphere. Thin-layer chro-

22) M.W. Rathke and A. Lindert, *Tetrahedron Lett.*, **1971**, 3995.

23) J.V. Forsch, I.T. Harrison, B. Lythgoe, and A.K. Saxena, *J. Chem. Soc. Perkin I*, **1974**, 2005; R.A. Ruden and R. Bonjouklian, *J. Am. Chem. Soc.*, **97**, 6892 (1975).

24) H. Kondo and S. Ohno, U.S. Patent 3134772 [*Chem. Abstr.*, **61**, 5736 (1964)]; G.R. Pettit, L.E. Houghton, J.C. Knight, and F. Bruscheiler, *J. Org. Chem.*, **35**, 2895 (1970).

matography (TLC) was conducted using Merck precoated Silica gel GF₂₅₄ plate and preparative TLC using 20×20 cm glass plate coated with 20 g of Merck silica gel PF₂₅₄₊₃₆₆. For column chromatography Merck silica gel with 0.06 to 0.20 mm particles or Merck alumina was used.

3 β -Acetoxy-20-methoxy-21-formyl-5 β -pregn-20-ene (8a)—This compound was prepared after the method of S. Bernstein.¹⁴ To a stirred solution of 2.0 g of pregnanolone acetate (7a) in 40 ml of trimethyl orthoformate was added 1.3 ml of 70% perchloric acid dropwise and at room temperature (20°). After an additional 5 min, the dark green reaction mixture was treated with 3 ml of pyridine and then added to saturated NaHCO₃. The precipitated 8a (1.445 g) was filtered and the filtrate was extracted with dichloromethane. The solvent was evaporated after drying on MgSO₄ and the residue was crystallized from ether to give an additional crop (0.287 g). Recrystallization from iso-Pr₂O-CH₂Cl₂ afforded colorless needles, mp 205–207°. Anal. Calcd. for C₂₅H₃₈O₄: C, 74.59; H, 9.52. Found: C, 74.68; H, 9.50. IR (KBr) cm⁻¹: 1715, 1650, 1595. NMR (CDCl₃) δ : 0.63 (18-CH₃), 0.98 (19-CH₃), 2.03 (OAc), 3.67 (OCH₃), 5.03 (3 α -H), 5.43 (21-H, d, J =7.5), 9.72 (CHO, d, J =7.5).

3 β -Acetoxy-21-methoxymethylidene-5 β -pregnan-20-one (9a)—A stirred solution of 2.00 g of 8a in a mixture of 30 ml of dry tetrahydrofuran and 20 ml of dry methanol was warmed at 50° and treated with 0.8 g of pyridine hydrobromide. After continued stirring for 35 min, 8a disappeared from TLC. The reaction mixture was immediately added to saturated NaHCO₃, extracted with benzene, washed with brine, and dried on MgSO₄. Evaporation of the solvent afforded the crystalline product (2.12 g) which consisted of 9a and 10a (about 1:1 mixture by NMR). It was then dissolved in 50 ml of dry *tert*-butanol and treated with 40 mg of potassium *tert*-butoxide at 35° for 20 min. The solution was neutralized by addition of 10% acetic acid, concentrated by a rotary evaporator, and extracted with benzene. The benzene extract was washed with 5% NaHCO₃, dried on MgSO₄, and evaporated. The pale yellow crystalline residue (2.08 g) was recrystallized from iso-Pr₂O-benzene to give 9a (1.51 g), mp 192–194°. Anal. Calcd. for C₂₅H₃₈O₄: C, 74.59; H, 9.52. Found: C, 74.45; H, 9.34. IR (KBr) cm⁻¹: 1720, 1670, 1580. NMR (CDCl₃) δ : 0.60 (18-CH₃), 0.97 (19-CH₃), 2.03 (OAc), 3.67 (OCH₃), 5.05 (3 α -H), 5.53 (21-H, d, J =12), 7.53 (22-H, d, J =12).

17 β -(2-Methoxy-3,6-dihydro-2H-pyran-5-yl)-5 β -androst-3 β -ol (11a)—A solution of dimsyl potassium was prepared by reacting 3.13 g of KH (24.7% in mineral oil) with 15 ml of anhydrous Me₂SO at room temperature followed by dilution with 15 ml of anhydrous tetrahydrofuran. A 12 ml portion of this solution was added by a syringe with stirring and at -2° to a combined solution of 1.0 g of 9a in 15 ml of tetrahydrofuran with 1.54 g of trimethylsulfonium iodide dissolved in 15 ml of Me₂SO. After the addition, the reaction mixture was stirred at -2° to 0° and then partitioned between ether and water. The organic layer was washed with saturated brine, dried on MgSO₄, and evaporated. The residual glassy product was dissolved in 50 ml of dry MeOH containing 3 drops of concentrated HCl and heated at 58–60° for 30 min. The solution was then made alkaline by addition of 10 ml of 30% KOH, and after heating at the same temperature for 1 hr, it was concentrated by a rotary evaporator, and partitioned between ether and H₂O. The ether layer was washed with saturated brine, dried on MgSO₄, and evaporated. The residue was chromatographed on 15 g of silica gel. Elution with benzene afforded 125 mg of furan (12a), and subsequent elution with a mixture of benzene and ether furnished 590 mg of 11a. 11a, mp 134–138° (MeOH). Anal. Calcd. for C₂₅H₄₀O₃: C, 77.27; H, 10.38. Found: C, 77.36; H, 10.13. NMR (CCl₄) δ : 0.55 (18-CH₃), 0.93 (19-CH₃), 3.9 (21-CH₂ and 3 α -H, broad), 3.32 (OCH₃), 4.57 (24-H, m), 5.30 (22-H, m). Acetate of 11a was obtained by acetylation with acetic anhydride and pyridine, mp 158–161° (iso-Pr₂O). Anal. Calcd. for C₂₇H₄₂O₄: C, 75.31; H, 9.83. Found: C, 75.23; H, 9.74. NMR (CCl₄) δ : 0.55 (18-CH₃), 0.97 (19-CH₃), 1.97 (OAc), 3.33 (OCH₃), 3.77 and 3.92 (21-CH₂), 4.57 (24-H, m), 4.97 (3 α -H), 5.23 (22-H, m). 12a, mp 144–145° (MeOH). Anal. Calcd. for C₂₃H₃₄O₂: C, 80.65; H, 10.01. Found: C, 80.68; H, 10.13. NMR (CCl₄) δ : 0.48 (18-CH₃), 0.97 (19-CH₃), 4.03 (3 α -H), 6.18 (22-H, diffused d, J =1), 7.12 (21-H, diffused s), 7.30 (23-H, t, J =1).

17 β -(2-Methoxy-3,6-dihydro-2H-pyran-5-yl)-5 β -androst-14-en-3 β -ol (11b)—A solution of 1.98 g of 3 β -acetoxy-20-methoxy-21-formyl-5 β -pregna-14,20-diene (8b, prepared from 7b according to the previous paper¹) in 60 ml of anhydrous MeOH was treated with 2.4 ml of 3 M pyridine hydrobromide in MeOH at 45° for 30 min. The product obtained by the same workup as described for 8a was dissolved in 100 ml of dry *tert*-butanol and the solution was kept at 30° with stirring while adding 100 mg of potassium *tert*-butoxide in two portions. After 35 min, the reaction mixture was neutralized with 1% AcOH and concentrated. The glassy product (2.0 g) isolated by ether extraction was identified as 9b by NMR (CCl₄) δ : 0.86 (18-CH₃), 0.96 (19-CH₃), 1.96 (OAc), 3.66 (OCH₃), 4.93 (3 α -H), 5.07 (15-H), 5.49 (21-H, d, J =12), 7.47 (22-H, d, J =12). A solution of dimsyl potassium was prepared by the reaction of 2.7 g of KH (24.7% in mineral oil) in 15 ml of Me₂SO followed by dilution with 15 ml of tetrahydrofuran. It was cooled at 0° and added by a syringe to a stirred solution of 9b and 3.06 g of trimethylsulfonium iodide in 30 ml of Me₂SO and 30 ml of tetrahydrofuran. After 20 min, the reaction was stopped by addition of AcOH and subjected to usual workup. The crude product was dissolved in 100 ml of MeOH containing 3 drops of concentrated HCl and the solution was heated at 55° for 20 min. By usual workup the brown semi-solid product which showed essentially 2 spots on TLC was obtained. Separation of the two components was made by chromatography on 25 g of silica gel eluting with benzene and benzene-ether mixtures. From initial fractions there was obtained 357 mg of furan (12b) which was identical with the sample prepared in the previous paper.¹ Later fractions afforded 1.2 g of 11b as crystalline mass. NMR (CCl₄) δ : 0.76 (18-CH₃), 0.98 (19-CH₃), 3.41 (OCH₃), 3.84 (3 α -H),

4.01 (21-CH₂), 4.71 (24-H), 5.20 (15-H), 5.50 (22-H). The acetate, mp 160–163° (iso-Pr₂O), was obtained by acetylation with acetic anhydride and pyridine. *Anal.* Calcd. for C₂₇H₄₀O₄: C, 75.76; H, 9.42. Found: C, 76.02; H, 9.59. NMR (CCl₄) δ : 0.77 (18-CH₃), 1.00 (19-CH₃), 2.00 (OAc), 3.36 (OCH₃), 3.8–4.1 (21-CH₂), 4.63 (24-H, broad), 5.00 (3 α -H), 5.46 (22-H, broad).

3 β -Acetoxy-17 β -(2-hydroxy-3,6-dihydro-2H-pyran-5-yl)-5 β -androstane (13a)—To a solution of 272 mg of the acetate of 11a in 10 ml of tetrahydrofuran was added 5 ml of HCl–KCl buffer (pH=1.2) and the mixture was kept at 45° with stirring for 2 days. The solution was poured to saturated NaHCO₃ and extracted with CH₂Cl₂. The extract was washed with brine, dried on MgSO₄, and evaporated. The residual crystalline mass was chromatographed on 10 g of alumina (neutral, activity IV) eluting with a mixture of benzene and hexane (1:1). After recovery of 26 mg of the starting material, 234 mg of dihydropyranol (13a) was obtained and crystallized from benzene–hexane, mp 142–147°. *Anal.* Calcd. for C₂₆H₄₀O₄: C, 74.96; H, 9.68. Found: C, 75.20; H, 9.88. NMR (CCl₄) δ : 0.56 (18-CH₃), 0.97 (19-CH₃), 1.97 (OAc), 3.98 (21-CH₂, diffused t, *J*=7), 4.97 (3 α -H), 5.27 (22-H).

3 β -Acetoxy-17 β -(2-hydroxy-3,6-dihydro-2H-pyran-5-yl)-5 β -androst-14-ene (13b)—To a solution of crude acetate obtained from 1.2 g of 11b in 50 ml of tetrahydrofuran was added 25 ml of HCl–KCl buffer (pH=1.2) and the mixture was stirred at 40° for 35 hr. The hydrolysis product isolated by extraction with CH₂Cl₂ was chromatographed on 45 g of alumina (neutral, activity, IV). Elution with benzene and benzene–ether mixtures afforded 802 mg of 13b. Analytical sample was recrystallized from iso-Pr₂O–hexane, mp 118–122°. *Anal.* Calcd. for C₂₆H₃₈O₄: C, 75.32; H, 9.24. Found: C, 75.54; H, 9.33. NMR (CCl₄) δ : 0.78 (18-CH₃), 0.99 (19-CH₃), 2.00 (OAc), 3.9–4.4 (21-H and 24-H), 5.00 (3 α -H), 5.50 (22-H). MS *m/e* (relative intensity): 414 (M⁺, 9), 396 (43), 336 (100).

3 β -Acetoxy-5 β -buf-20(22)-enolide (14a)—A solution of 300 mg of 13a in 20 ml of acetone was titrated with Jones reagent at 0°. The reaction product isolated by usual manner was filtered through a column of 10 g of silica gel using benzene and benzene–ether mixtures as eluting solvents to give 220 mg of 14a. Recrystallization from ether afforded colorless plates (180 mg), mp 85–88°. *Anal.* Calcd. for C₂₆H₃₈O₄: C, 75.32; H, 9.24. Found: C, 75.10; H, 9.36. IR (KBr) cm⁻¹: 1730. NMR (CCl₄) δ : 0.55 (18-CH₃), 0.97 (19-CH₃), 1.97 (OAc), 2.92 (23-CH₂, broad), 4.60 (21-CH₂, broad), 5.57 (22-H, diffused t, *J*=4).

3 β -Acetoxy-5 β -bufa-14,20(22)-dienolide (14b)—A solution of 670 mg of 13b in 45 ml of acetone was titrated with Jones reagent at 0° over 20 min. Usual workup afforded 575 mg of 14b which was recrystallized from iso-Pr₂O–CH₂Cl₂, mp 210–213°. NMR (CCl₄) δ : 0.80 (18-CH₃), 1.00 (19-CH₃), 2.01 (OAc), 3.01 (23-CH₂, broad), 4.73 (21-CH₂, broad), 5.00 (3 α -H), 5.16 (15-H), 5.70 (22-H, diffused t, *J*=4). *Anal.* Calcd. for C₂₆H₃₆O₄: C, 75.69; H, 8.80. Found: C, 75.53; H, 9.05.

5 β -Buf-20(22)-enolide (14c)—This compound was prepared from 5 β -pregnan-20-one²⁵ by carrying out the same reaction sequence described for 14a and 14b, mp 180–181° from cyclohexane (lit.,¹⁵) mp 179–180° [α]_D = –13.6° (CHCl₃, *c*=3.0) (lit.,¹⁵) –11.7°. *Anal.* Calcd. for C₂₄H₃₆O₂: C, 80.85; H, 10.18. Found: C, 81.02; H, 10.31. IR (KBr) cm⁻¹: 1740. NMR (CDCl₃) δ : 0.57 (18-CH₃), 0.93 (19-CH₃), 3.01 (23-CH₂, diffused s), 4.75 (21-CH₂, m), 5.65 (22-H, diffused t, *J*=4.5). The sample obtained here was also identified by direct comparison of the NMR chart with that of authentic sample through the courtesy of Prof. Sarel.¹⁷

Physical data of characterized intermediates are given below. 20-Methoxy-21-formyl-5 β -pregn-20-ene (not crystallized). NMR (CCl₄) δ : 0.60 (18-CH₃), 0.92 (19-CH₃), 3.68 (OCH₃), 5.37 (21-H, d, *J*=7), 9.73 (22-H, d, *J*=7). 21-Methoxymethylidene-5 β -pregnan-20-one (mp 156.5–157.5° from hexane–CH₂Cl₂). *Anal.* Calcd. for C₂₃H₃₆O₂: C, 80.30; H, 10.55. Found: C, 80.44; H, 10.31. NMR (CCl₄) δ : 0.55 (18-CH₃), 0.92 (19-CH₃), 3.70 (OCH₃), 5.48 (21-H, d, *J*=13), 7.48 (22-H, d, *J*=13).

DDQ Dehydrogenation of Buf-20(22)-enolides—1) To a solution of 23 mg of 14a in 4.5 ml of anhydrous dioxane containing 50 mg of toluene-*p*-sulfonic acid was added 30 mg of DDQ. The solution was refluxed with stirring for 4.5 hr and then partitioned between ether and H₂O. The ether solution was washed with saturated NaHCO₃ and brine, dried on MgSO₄, and evaporated. The residue was revealed by integration of olefinic protons (NMR) to be a 7:3 mixture of 16a and 15a. The major isomer (16a) was isolated by preparative TLC (benzene–ethyl acetate=9:1) and crystallized from iso-Pr₂O–CH₂Cl₂, mp 204–209°. *Anal.* Calcd. for C₂₆H₃₆O₄: C, 75.69; H, 8.80. Found: C, 75.81; H, 8.68. IR (KBr) cm⁻¹: 1715, 1620. NMR (CDCl₃) δ : 0.95 (18-CH₃), 0.99 (19-CH₃), 2.03 (OAc), 5.08 (3 α -H and 21-CH₂), 5.73 (23-H, d, *J*=10), 7.07 (22-H, d, *J*=10). NMR data of minor isomer 15a was obtained from the spectrum of the crude product by subtracting the peaks due to 16a²⁶: 0.99 (19-CH₃), 1.23 (18-CH₃), 4.83 (21-CH₂), 5.70 (23-H, d, *J*=10), 7.43 (22-H, d, *J*=10). Hydrogen chloride catalyzed dehydrogenation in dimethoxyethane proceeded at room temperature giving essentially the same result.

2) A solution of 50 mg of 14c in 14 ml of dioxane containing 14 mg of toluene-*p*-sulfonic acid and 56 mg of DDQ was refluxed for 4 hr. The crude product obtained by usual workup was subjected to preparative TLC (CHCl₃–benzene=3:1) where, in addition to 6.2 mg of the starting material, 29.7 mg of a mixture of bufa-17,22-dienolide isomers (15c and 16c) was isolated, mp 171–174° (iso-Pr₂O). Ratio of 16c to 15c was 7:3 by NMR.²⁶ *Anal.* Calcd. for C₂₄H₃₄O₂: C, 81.31; H, 9.67. Found: C, 81.18; H, 9.42. IR (KBr)

25) M. Fetizon, F.J. Kakis, and V. Ignatiadou-Ragoussis, *J. Org. Chem.*, **38**, 4308 (1973).

26) Peak assignments were based on the ref. 15).

cm⁻¹: 1720, 1625, 1575. NMR (CCl₄) δ : **15c**, 4.78 (21-CH₂), 5.62 (23-H, d, $J=10$), 7.40 (22-H, d, $J=10$); **16c**, 5.03 (21-CH₂), 5.67 (23-H, d, $J=10$), 7.03 (22-H, d, $J=10$).

3 β -Acetoxy-5 β -bufa-20,22-dienolide (17a)—To a solution of 20.7 mg of bufenolide **14a** in 4 ml of CH₂Cl₂ was added 0.5 ml of 0.1 M Br₂ in CH₂Cl₂ and the mixture was stirred at room temperature for 2 hr. The CH₂Cl₂ solution was then washed with H₂O, dried on MgSO₄, and evaporated. The residue was dissolved in a mixture of 1 ml of dimethyl formamide (DMF) and 0.5 ml of DBU and heated at 60° for 1 hr. The product isolated by ether extraction was purified by preparative TLC (benzene-AcOEt=9:1) and crystallized from iso-Pr₂O, mp 160–164° (8 mg). Anal. Calcd. for C₂₆H₃₆O₄: C, 75.69; H, 8.80. Found: C, 75.75; H, 8.87. NMR (CCl₄) δ : 0.53 (18-CH₃), 0.97 (19-CH₃), 1.97 (OAc), 4.93 (3 α -H), 6.01 (23-H, d, $J=10.5$), 7.05 (22-H, m), 7.13 (21-H, diffused s).

5 β -Bufa-20,22-dienolide (17c)—This compound was obtained in 61% yield by dehydrogenation of **14c** using bromination-dehydrobromination technique described above. Analytical sample was crystallized from benzene-petroleum ether, mp 192–194° (lit.¹⁵) 194–196°. Anal. Calcd. for C₂₄H₃₄O₂: C, 81.31; H, 9.67. Found: C, 81.17; H, 9.91. IR (KBr) cm⁻¹: 1720, 1630, 1530. NMR (CCl₄) δ : 0.55 (18-CH₃), 0.95 (19-CH₃), 6.11 (23-H, d, $J=10$), 7.13 (22-H, m), 7.22 (21-H, diffused s).

3 β -Acetoxy-20-hydroxy-21-bromo-5 β -chol-22-en-24-oic acid lactone (20)—1) A solution of 100 mg of **14a** in a mixture of 1 ml of trimethylsilylimidazole, 1 ml of bistrimethylsilylacetamide and 0.4 ml of trimethylchlorosilane was left stand at room temperature. After 10 days, the solution was evaporated *in vacuo*. The residue was dissolved in 2 ml of CCl₄ and brominated at -15° and with stirring by dropwise addition of 0.5 M Br₂ in CCl₄. The reaction mixture was diluted with CH₂Cl₂, washed with water, dried on MgSO₄, and evaporated. Purification of the product by preparative TLC followed by crystallization from MeOH afforded **20**, mp 248–251°. Anal. Calcd. for C₂₆H₃₇O₄Br: C, 63.28; H, 7.56. Found: C, 63.08; H, 7.66. NMR (CDCl₃) δ : major isomer at C₂₀—0.80 (18-CH₃), 0.97 (19-CH₃), 2.03 (OAc), 3.66 (21-CH₂, s), 5.05 (3 α -H), 6.13 (23-H, d, $J=6$), 7.30 (22-H, d, $J=6$); minor isomer—0.60 (18-CH₃), 0.95 (19-CH₃), 3.30, 3.47 (21-CH₂, d, $J=12$), 6.16 (23-H, d, $J=6$), 7.50 (22-H, d, $J=6$). MS m/e (relative intensity): 434, 432 (M⁺-AcOH, 100), 419, 417 (29), 353 (40), 257 (36), 215 (33). IR (KBr) cm⁻¹: 1755, 1735.

2) A solution of 60 mg of **14a** in 0.4 ml of tetrahydrofuran was added during 5 min to 0.8 ml of 0.18 M iso-Pr₂NLi in tetrahydrofuran with stirring and at -78°. After 20 min, 0.25 ml of 0.58 M Br₂ in CH₂Cl₂ was added rapidly to the enolate solution and the mixture was allowed to warm to room temperature. The crude product obtained by usual workup was subjected to preparative TLC (cyclohexane-ether-AcOEt=4:2:1), by which 5.5 mg of **20** and 9 mg of **14a** were isolated.

3 β -Acetoxy-5 β -bufa-14,20,22-trienolide (14-anhydrobufalin acetate) (21)—A solution of 25 mg of **14b** and 90 mg of S in CS₂ was evaporated and the residue was heated at 200° for 10 min (disappearance of **14b** from TLC). After cooling, the organic product was subjected to preparative TLC (cyclohexane-ether-AcOEt=4:2:1) to give 2.5 mg of **21**, which was identified with an authentic sample prepared from natural bufalin²⁷) by comparison of TLC, IR, NMR, and MS.

3 β -Acetoxy-14 β ,15 β -epoxy-5 β -buf-20(22)-enolide (22)—A stirred solution of 37 mg of **14b** in 1.5 ml of acetone and 0.3 ml of H₂O was cooled at 0° and treated with 0.046 ml of 70% HClO₄ and 18.6 mg of N-bromoacetamide dissolved in 0.3 ml of H₂O. After stirring for 30 min, the reaction mixture was mixed with Na₂SO₃ solution and extracted with ether. The ether solution was washed with saturated NaHCO₃, dried on MgSO₄, and evaporated. The residue was chromatographed on 1 g of alumina (basic, activity V) eluting with benzene. The epoxide (**22**, 32 mg) which showed single spot on TLC was crystallized from ether, mp 155–157°. Anal. Calcd. for C₂₆H₃₆O₅: C, 72.86; H, 8.47. Found: C, 72.89; H, 8.49. NMR (CCl₄) δ : 0.87 (18-CH₃), 0.97 (19-CH₃), 1.97 (OAc), 2.87 (23-H, broad), 3.30 (15 α -H, s), 4.67 (21-H, broad), 4.90 (3 α -H broad), 5.50 (22-H, diffused t, $J=4$).

Resibufogenin Acetate (23)—To a stirred suspension of 42.8 mg of **22** in 2 ml of ether was added successively 1 ml of 10% AcOK-AcOH and 2 ml of 0.1 M Br₂ in AcOH. The mixture was stirred at room temperature overnight and poured to saturated NaHCO₃. Extraction with ether followed by usual workup afforded pale brown foam. It was then dissolved in 1.5 ml of DMF and 0.5 ml of DBU and warmed to 60° over 1 hr. The product (35 mg) isolated by ether extraction showed two partially overlapped spots on TLC and revealed by NMR to be a 1:1 mixture of resibufogenin acetate **23** and starting material **22**. **23** was isolated by preparative TLC (acetone-cyclohexane=1:3) and crystallized from MeOH-ether, mp 229–234°. The spectroscopic data (IR, UV, NMR, and MS) were entirely identical with those of authentic sample prepared from natural resibufogenin. IR (CHCl₃) cm⁻¹: 1718, 1625, 1530. NMR (CCl₄) δ : 0.76 (18-CH₃), 1.00 (19-CH₃), 1.98 (OAc), 3.36 (15 α -H, s), 4.96 (3 α -H, m), 6.07 (23-H, d, $J=10$), 7.10 (21-H, d, $J=2.5$), 7.63 (22-H, dd, $J=10, 2.5$). MS m/e (relative intensity): 426 (M⁺, 10), 366 (100), 351 (22), 338 (23), 312 (14), 275 (32), 215 (81).

Acknowledgement This research was supported by a Grant 987099 administered by the Ministry of Education, Science and Culture which are gratefully acknowledged. The authors also express their thanks to Mr. Morikoshi for measurements of NMR and mass spectra and to Mr. Takami for elemental analyses.

27) G.R. Pettit, Y. Kamano, F. Bruschweiler, and P. Brown, *J. Org. Chem.*, **36**, 3736 (1971).